JP2016526531A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526531A5
JP2016526531A5 JP2016518498A JP2016518498A JP2016526531A5 JP 2016526531 A5 JP2016526531 A5 JP 2016526531A5 JP 2016518498 A JP2016518498 A JP 2016518498A JP 2016518498 A JP2016518498 A JP 2016518498A JP 2016526531 A5 JP2016526531 A5 JP 2016526531A5
Authority
JP
Japan
Prior art keywords
dose
administered
viral particles
particles per
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016518498A
Other languages
English (en)
Japanese (ja)
Other versions
JP6797680B2 (ja
JP2016526531A (ja
Filing date
Publication date
Priority claimed from GB201310698A external-priority patent/GB201310698D0/en
Priority claimed from GB201405140A external-priority patent/GB201405140D0/en
Priority claimed from GB201406509A external-priority patent/GB201406509D0/en
Application filed filed Critical
Priority claimed from PCT/EP2014/062284 external-priority patent/WO2014198852A2/en
Publication of JP2016526531A publication Critical patent/JP2016526531A/ja
Publication of JP2016526531A5 publication Critical patent/JP2016526531A5/ja
Application granted granted Critical
Publication of JP6797680B2 publication Critical patent/JP6797680B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016518498A 2013-06-14 2014-06-12 Ｂ型アデノウイルスのための投与計画および製剤 Active JP6797680B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB201310698A GB201310698D0 (en) 2013-06-14 2013-06-14 Method
GB1310698.4 2013-06-14
GB1405140.3 2014-03-22
GB201405140A GB201405140D0 (en) 2014-03-22 2014-03-22 Method
GB201406509A GB201406509D0 (en) 2014-04-10 2014-04-10 Method
GB1406509.8 2014-04-10
PCT/EP2014/062284 WO2014198852A2 (en) 2013-06-14 2014-06-12 A dosing regime and formulations for type b adenoviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020151615A Division JP2020203932A (ja) 2013-06-14 2020-09-09 Ｂ型アデノウイルスのための投与計画および製剤

Publications (3)

Publication Number Publication Date
JP2016526531A JP2016526531A (ja) 2016-09-05
JP2016526531A5 true JP2016526531A5 (enExample) 2016-10-20
JP6797680B2 JP6797680B2 (ja) 2020-12-16

Family

ID=51162703

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016518498A Active JP6797680B2 (ja) 2013-06-14 2014-06-12 Ｂ型アデノウイルスのための投与計画および製剤
JP2020151615A Pending JP2020203932A (ja) 2013-06-14 2020-09-09 Ｂ型アデノウイルスのための投与計画および製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020151615A Pending JP2020203932A (ja) 2013-06-14 2020-09-09 Ｂ型アデノウイルスのための投与計画および製剤

Country Status (12)

Country Link
US (2) US11173186B2 (enExample)
EP (2) EP3007711B1 (enExample)
JP (2) JP6797680B2 (enExample)
KR (3) KR20210054067A (enExample)
CN (2) CN112516179A (enExample)
AU (2) AU2014280123B2 (enExample)
BR (1) BR112015030881A2 (enExample)
CA (2) CA3176971A1 (enExample)
IL (1) IL243071B (enExample)
RU (1) RU2671558C2 (enExample)
SG (1) SG11201510064WA (enExample)
WO (1) WO2014198852A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
CN110461323A (zh) * 2017-03-31 2019-11-15 绪方久修 溶瘤病毒的增殖方法和抗肿瘤剂
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
AU2019244150B2 (en) * 2018-03-30 2024-11-28 Tomoki Todo Swelling-suppressive oncolytic virus
EP4037705A4 (en) * 2019-09-30 2024-02-21 Candel Therapeutics, Inc. Combination gmci and atri cancer treatment
CN114469938A (zh) * 2020-10-27 2022-05-13 中国医学科学院药物研究所 化合物bix02189在制备抗流感病毒药物中的应用
CN114601838B (zh) * 2022-04-29 2023-10-27 广东龙帆生物科技有限公司 一种azd8055在制备用于抗腺病毒感染的药物中的用途
WO2024042231A1 (en) * 2022-08-26 2024-02-29 Universite De Namur Adenovirus-based adjuvants for cancer treatment
KR20260018078A (ko) 2023-05-25 2026-02-06 디스패치 바이오테라퓨틱스, 인크. 암을 치료하기 위한 표적으로서의 합성 암 항원
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170269A3 (en) 1984-08-02 1987-09-23 Kao Corporation Medicated cosmetic compositions
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE19648650C2 (de) 1996-01-29 1998-07-02 Schering Ag Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
JP2001519175A (ja) * 1997-10-09 2001-10-23 プロ − バイラス，インコーポレイテッド ウイルスを用いた新生物の処置
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
PT1137792E (pt) 1998-12-09 2007-08-10 Therion Biolog Corp Vector recombinado que exprime moléculas costimulantes múltiplas e as suas utilizações
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
CN1347450A (zh) 1999-04-09 2002-05-01 阿文蒂斯药物股份有限公司 用于保存感染性重组腺病毒的组合物
US7279318B1 (en) 1999-06-09 2007-10-09 Hybrid Systems Limited Modification of biological elements
ATE403715T1 (de) 1999-08-09 2008-08-15 Targeted Genetics Corp Erhöhung der expression einer einzelsträngigen, heterologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2005010149A2 (en) * 2003-07-18 2005-02-03 Onyx Pharmaceuticals, Inc. Subgroup b adenoviral vectors for treating disease
JP4948174B2 (ja) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
CA2836987C (en) * 2004-05-26 2016-07-05 Psioxus Therapeutics Limited Chimeric adenoviruses for use in cancer treatment
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
WO2007027860A2 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
CN1961961B (zh) 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
RU2382884C2 (ru) 2006-07-10 2010-02-27 Александр Владимирович Дидин Сферическая объемная роторная машина и способ работы сферической объемной роторной машины
JP5448840B2 (ja) * 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
US20110243897A1 (en) 2008-12-11 2011-10-06 Leonard William Seymour Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
PH12013502531A1 (en) 2011-08-23 2014-01-20 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2013074507A2 (en) 2011-11-14 2013-05-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CA2871711A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
WO2015040234A1 (en) 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
KR102380402B1 (ko) 2014-04-03 2022-03-31 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
JP2017529070A (ja) 2014-08-27 2017-10-05 サイオクサス セラピューティクス リミテッド アデノウイルスの製造方法
US11000559B2 (en) 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein

Similar Documents

Publication Publication Date Title
JP2016526531A5 (enExample)
RU2015152860A (ru) Режим введения и составы для аденовирусов типа в
Yasinjan et al. Immunotherapy: a promising approach for glioma treatment
Basak et al. Tumor-associated macrophages: an effective player of the tumor microenvironment
Zhu et al. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Huang et al. Time-programmed delivery of sorafenib and anti-CD47 antibody via a double-layer-gel matrix for postsurgical treatment of breast cancer
Seicean et al. New targeted therapies in pancreatic cancer
JP2012067116A5 (enExample)
JP2019065028A5 (enExample)
JP2016530280A5 (enExample)
JP2017031213A5 (enExample)
JP2013189456A5 (enExample)
JP2020509024A5 (enExample)
JP2015187125A5 (enExample)
RU2015144666A (ru) Терапия для лечения рака, включающая антитела против клаудина 18.2
Frieboes et al. Chloroquine-mediated cell death in metastatic pancreatic adenocarcinoma through inhibition of autophagy
JP2016515586A5 (enExample)
Karapetyan et al. Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations
JP2016501528A5 (enExample)
JP2017503846A5 (enExample)
Wang et al. The pros and cons of dying tumour cells in adaptive immune responses
Holtermann et al. Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors: A. Holtermann et al.
Jiang et al. Low‐dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer
Warricker et al. The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma
He et al. Role of tumor-associated macrophages in breast cancer immunotherapy